Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Eli lilly and company save search
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
review cancer treatment advanced china
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 0.21%
H: 1.49%
C: -0.06%
treatment advanced china
Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.08%
H: 0.15%
C: -0.44%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.06%
H: 0.96%
C: 0.26%
CAH | $108.19 2.07% 0.0% 1.5M
|
Distribution Services
|
| O: 0.02%
H: 0.73%
C: -0.02%
LNTH | News | $63.8 2.36% 2.3% 800K
|
Health Technology
|
| O: 0.1%
H: 1.98%
C: -0.08%
reach cancer treatment market
FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’sAgency to convene an advisory committee to consider the drug
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -2.29%
fda drug approval treatment
Listeria Monocytogenes Infections Treatment Global Market Report 2024: Global Expansion in Listeria Monocytogenes Treatment Sector Predicted Amid Rising Foodborne Disease Incidence
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -2.14%
H: 0.0%
C: -0.63%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.71%
H: 0.0%
C: 0.0%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.87%
H: 0.21%
C: -2.23%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.89%
H: 0.41%
C: 0.1%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 2.44%
C: 1.54%
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.56%
H: 0.49%
C: -0.12%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.16%
H: 0.43%
C: -2.76%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.28%
H: 0.93%
C: 0.75%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.21%
H: 0.34%
C: 0.07%
disease report treatment expansion global infections market
Global Epidural Abscess Treatment Market Report 2024 - Treatment Advances and Digital Health Technologies Shaping the Future of Epidural Abscess Care
Published: 2024-02-12 (Crawled : 15:30) - prnewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.57%
H: 0.04%
C: -1.74%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.46%
H: 1.04%
C: 0.97%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: -0.48%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.02%
H: 0.46%
C: -0.14%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.83%
H: 0.7%
C: -0.27%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.77%
H: 0.46%
C: 0.41%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.4%
H: 1.6%
C: 1.54%
report health treatment care global market
Global Erectile Dysfunction Treatment Market Insights Report 2024-2029 Featuring Leading Vendors - Bayer, Pfizer, Coloplast, Eli Lilly and Company, and Boston Scientific
Published: 2024-02-10 (Crawled : 04:20) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
report treatment global market
Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal
Published: 2024-02-01 (Crawled : 22:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.27%
H: 2.04%
C: 2.02%
corporation series treatment study
Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight
Published: 2024-01-15 (Crawled : 22:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
drug treatment heart market
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.77%
H: 0.49%
C: 0.49%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.2%
H: 1.7%
C: 1.3%
rient-16 treatment results study
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Published: 2023-12-04 (Crawled : 23:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
VNDA | $5.11 2.82% 2.74% 2.4M
|
Health Technology
|
| O: 2.08%
H: 1.53%
C: 0.76%
drug food treatment pharmaceuticals application
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
Published: 2023-12-01 (Crawled : 23:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
jaypirca fda approved treatment leukemia
Acute Myocardial Infarction Treatment Market to Show Immense Growth at a CAGR of 7.7% During the Study Period (2019-2032), Predicts DelveInsight
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
treatment show growth study market
Pediatric Neuroblastoma Treatment Global Market Report 2023, Featuring Profiles of United Therapeutic, Pfizer, Baxter, MacroGenics, Amgen and More
Published: 2023-11-14 (Crawled : 22:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.44%
H: 0.0%
C: 0.0%
report treatment global market
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Published: 2023-11-08 (Crawled : 21:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.29%
H: 3.0%
C: 1.89%
fda obesity treatment medical tirzepatide
OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 4.2%
H: 0.83%
C: 0.49%
obesity metabolic disorders series treatment
Innovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity
Published: 2023-10-30 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
ibi362 obesity metabolic favorable treatment study benefits
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
Published: 2023-10-26 (Crawled : 00:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.68%
H: 0.0%
C: 0.0%
bge-105 agonist treatment collaboration trial tirzepatide
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-26 (Crawled : 23:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
fda active treatment
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
Published: 2023-10-24 (Crawled : 14:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
thn391 treatment dementia trial potential results
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.